Spectrum Pharma (SPPI) Announces Interim Data from Phase 2 Clinical Study Evaluating Poziotinib in EGFR Exon 20 Mutant
Tweet Send to a Friend
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) announced the oral presentation of interim data from a Phase 2 clinical study evaluating poziotinib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
